

This is a repository copy of *Specificity of the Metallothionein-1 Response by Cadmium-Exposed Human Urothelial Cells*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/143632/>

Version: Accepted Version

Article:

McNeill, Rhiannon Victoria, Mason, Andrew Stephen orcid.org/0000-0002-8222-3974, Hodson, Mark Edward orcid.org/0000-0002-8166-1526 et al. (2 more authors) (2019) Specificity of the Metallothionein-1 Response by Cadmium-Exposed Human Urothelial Cells. International Journal of Molecular Sciences. ISSN 1422-0067

<https://doi.org/10.3390/ijms20061344>

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



Research Article

Specificity of the Metallothionein-1 Response by Cadmium-Exposed Human Urothelial Cells

Rhiannon V. McNeill^{1,4}, Andrew S. Mason¹, Mark Hodson², James W.F. Catto³, Jennifer Southgate^{1*}.

¹Jack Birch Unit for Molecular Carcinogenesis, York Biomedical Research Institute, Department of Biology and

²Department of Environment and Geography, University of York, York YO10 5DD, United Kingdom.

³Academic Urology Unit, University of Sheffield, Sheffield, UK.

⁴current address: Department of Psychiatry, Psychotherapy and Psychosomatic Medicine, University Hospital of Frankfurt, Frankfurt, Germany.

*Correspondence: j.southgate@york.ac.uk

Received: date; Accepted: date; Published: date

Abstract: Occupational and environmental exposure to cadmium is associated with the development of urothelial cancer. The metallothionein (MT) family of genes encodes proteins that sequester metal ions and modulate physiological processes, including zinc homeostasis. Little is known about the selectivity of expression of the different MT isoforms. Here, we examined the effect of cadmium exposure on MT gene and isoform expression by normal human urothelial (NHU) cell cultures. Baseline and cadmium-induced MT gene expression was characterized by next generation sequencing and RT-PCR; protein expression was assessed by western blotting using isoform-specific antibodies. Expression of the zinc transporter-1 (*SLC30A1*) gene was also assessed. NHU cells displayed transcription of *MT-2A*, but neither *MT-3* nor *MT-4* genes. Most striking was a highly inducer-specific expression of MT-1 genes, with cadmium inducing transcription of *MT-1A*, *MT-1G*, *MT-1H* and *MT-1M*. Whereas *MT-1G* was also induced by zinc and nickel ions and *MT-1H* by iron, both *MT-1A* and *MT-1M* were highly cadmium-specific, which was confirmed for protein using isoform-specific antibodies. Protein but not transcript endured post exposure, probably reflecting sequestration. *SLC30A1* transcription was also affected by cadmium ion exposure, potentially reflecting perturbation of intracellular zinc homeostasis. We conclude that human urothelium displays a highly inductive profile of MT-1 gene expression, with two isoforms identified as highly specific to cadmium providing candidate transcript and long-lived protein biomarkers of cadmium exposure.

Keywords: Metallothionein, urothelium, urothelial cancer, cadmium exposure, zinc transporter

1. Introduction

Occupational and environmental exposure to cadmium has increased as a result of the burning of fossil fuels and widespread use of the heavy metal in anthropological activities, such as battery production, electroplating, smelting and soldering (reviewed [1]). Cadmium ions accumulate in the body in an almost irreversible manner [2], as the metal cannot be metabolized to a less toxic species [3] and has a low excretion rate [4]. This is thought to be due to intracellular sequestration of cadmium ions by metal-binding proteins [5–7]. An association between cadmium exposure and bladder (urothelial) carcinogenesis has been reported, with higher cadmium concentrations demonstrated in the blood [8] and urine [9–11] of patients with bladder cancer. *In vitro* research supports these correlative studies, with malignant transformation of the immortalized RWPE-1, TLR1215, 16HBE and UROtsa cell lines reported after extended chronic cadmium exposure [12–15]. The bladder stores

concentrated urine prior to voiding, meaning that the urothelial lining of the bladder, which functions as one of the tightest epithelial barriers [16], is potentially exposed to excreted xenobiotics [16–18]. It is not known whether exposure to urinary cadmium is limited by the presence of an intact urinary barrier.

The metallothioneins (MTs) are a superfamily of low-molecular weight (~6 kDa), cysteine-rich proteins that are induced by and bind a range of metal ions, including cadmium [19,20]. Through this sequestration of metal ions MTs are considered to play a primary role in metal detoxification [21,22], but also metal (e.g. zinc) homeostasis [23–25] and the scavenging of reactive oxygen species (ROS) [26,27]. MT involvement in the bodily response to cadmium exposure has been well-documented, with numerous studies demonstrating cadmium-induced MT expression both in vitro [28–34] and in vivo [35,36].

Direct binding of MT protein to cadmium ions [37,38] results in a MT-cadmium complex that is highly resistant to degradation [5–7]. In man, four main MT subfamilies exist (MT-1, MT-2/2A, MT-3 and MT-4), with MT-1 consisting of nine isoforms (-A, -B, -E, -F, -G, -H, -L, -M, -X) [39] each encoded on individual genes. It is predicted that the individual MT isoforms have distinct properties including structure [40–41], tissue- and inducer-specific expression [22,34,42–47], induction rate [48], translational efficiency [41] and degradation rate [49,50]. Cadmium is reported to be the most potent inducer of MT expression [51]. This offers the potential that individual MT isoforms may be utilized as specific biomarkers of human exposure to cadmium, although it remains unclear which isoform(s) are responsible for cadmium sequestration. This lack of discrimination is largely due to the high homology between isoforms and the lack of discriminatory reagents, with no validated antibodies able to distinguish MT-1 and MT-2 subfamilies, nor the different MT-1 isoforms [41,52].

MTs are reported to work cooperatively with zinc transporters to regulate cellular zinc homeostasis, potentially by modulating cellular zinc ion concentration [39], although the exact mechanisms are unknown. Thus, a possible consequence of exposure to cadmium ions may be altered cellular zinc homeostasis. Cadmium and zinc possess highly similar properties, and it has been shown that cadmium can substitute for zinc in biological systems [53]. This can disrupt the normal functioning of various biological pathways [54,55], thus indirectly influencing processes involved in carcinogenesis such as cell proliferation and metastasis [56].

Our aims were to investigate MT isoform expression and specificity of induction in human urothelium under baseline and cadmium-exposed conditions, using a well-characterised normal human urothelial (NHU) cell culture system that includes polarized differentiated NHU cell sheets possessing tight barrier function [57,58]. Prior to cadmium exposure, cellular growth assays were performed to assess cytotoxicity. We next exposed NHU cells to a variety of potential MT inducers, including reactive oxygen species (ROS) [59,60], essential metals [44,61–66] and heavy metals [67–70] to define the specificity of response. Previously unpublished MT-1 isoform-specific antibodies were used to discriminate between MT-1 isoform proteins. Lastly, we determined whether transcription of the free zinc efflux regulator, zinc transporter-1 (*SLC30A1*) [71], altered as a consequence of cadmium exposure. These results revealed that MT isoform expression was inducer-specific and that abundance of both *MT-1A* and *MT-1M* transcript and protein was highly cadmium-specific, highlighting their potential as biomarkers of exposure. Cadmium was able to penetrate an intact urothelial barrier and effected transcriptional upregulation of *SLC30A1*, indicating a potential route for cadmium uptake and subsequent substitution in zinc homeostatic mechanisms.

2. Results

2.1 Influence of cadmium on NHU cell culture growth and uptake of cadmium across an intact urothelial barrier

Exposure of non-differentiated NHU cells to cadmium revealed that cell growth was unaffected by concentrations $\leq 10 \mu\text{M}$ CdCl_2 whilst exposure to $20 \mu\text{M}$ CdCl_2 resulted in distinct cytotoxicity (Fig 1A). Replication in a second independent cell line confirmed that exposure to $10 \mu\text{M}$ CdCl_2 did not

affect NHU cell growth (Fig 1B) and this concentration was therefore selected for further experiments. When differentiated NHU cell cultures (three independent cell lines) were grown on permeable membranes in triplicate and exposed apically to 10 μM CdCl_2 for 72 hours, no effect was seen on barrier function (control versus cadmium-exposed transepithelial electrical resistance (TEER) of $3.24 \pm 0.48 \text{ k}\Omega\cdot\text{cm}^2$ versus $3.17 \pm 0.52 \text{ k}\Omega\cdot\text{cm}^2$, mean \pm SEM; $P=0.93$; Table S1). The barrier was retained during CdCl_2 exposures of at least 7 days, over which time the TEER increased in the cadmium-exposed culture to 1.8 fold over control. Analysis of cell lysates by inductively coupled plasma optical emission spectroscopy (ICP-OES) revealed an intracellular cadmium concentration of 0.94 μM in lysates from cadmium-exposed cultures compared to 0.08 μM for control cultures.




Figure 1. Biomass growth assays for *in vitro* NHU cell cultures exposed to cadmium. AlamarBlue® assays were performed over 7 days on NHU cell cultures seeded at 6×10^4 cells/cm². (A) NHU cells were exposed to a range of cadmium concentrations from 0 to 20 μM ($n=1$ independent cell line). Each data point represents mean percentage reduction in AlamarBlue® \pm S.D. from three replicate cultures. (B) NHU cells were exposed to 10 μM CdCl_2 for up to 7 days. Data points represent mean percentage reduction in AlamarBlue® \pm S.D. from two independent NHU cell lines, each performed in triplicate.

2.2 Baseline and cadmium-induced MT transcription in NHU cells

NHU cells maintained in culture in non-differentiated and differentiated states were examined for baseline expression of MT genes. Analysis by mRNA-seq of non-differentiated NHU cells revealed high expression of *MT-1E* and *MT-1X* and low expression of *MT-1A*, *MT-1B*, *MT-1F* and *MT-1G*; there was no detection of *MT-1H* or *MT-1M* transcripts (Fig 2A). *MT-2A* expression was three times greater than all the MT-1 genes combined. No expression was detected for *MT-3* or *MT-4*. In almost all cases where MT gene expression was detected in non-differentiated NHU cells, the expression was reduced in the differentiated state. This was most striking for *MT-2A* ($\log_2FC=4.2$; $q=4.08 \times 10^{-3}$) and *MT-1E* ($\log_2FC=1.5$; $q=4.0 \times 10^{-4}$), although between-donor variation prohibited statistical significance for many genes with lower expression. The apparent exception was *MT-1X*, where the average expression increased in the differentiated state. However, this was inconsistent between donors, and the differential expression was non-significant. Interestingly, *MT-1L*, which generates a transcript with a premature stop codon [72], was expressed at similar abundance to *MT-1E* in the non-differentiated cells, but with a much greater downregulation in the differentiated state ($\log_2FC=5.4$; $q=8.4 \times 10^{-4}$). Previous reports of a truncation-rescuing polymorphism [73] was not identified in these donors, so while *MT-1L* is unlikely to form a functional protein, it may play a role in MT-1 transcript regulation. Expression was detected for *SLC30A1* in both non-differentiated and differentiated states (Fig 2A), but there was no significant differentiation-associated change in expression.

RT-PCR results supported the NGS data, although the variability in transcript detection in non-differentiated NHU cells indicated a potentially inducible state (Fig 2B). Differentiated NHU cell cultures revealed a more consistent baseline expression of several MT-1 genes, particularly *MT-1X* (Fig 2C).

Exposure to cadmium ions caused a massive induction of all eight MT-1 genes (*MT-1A*, *MT-1B*, *MT-1E*, *MT-1F*, *MT-1G*, *MT-1H*, *MT-1M*, *MT-1X*) within 12 hours of initial exposure, as demonstrated by the RT-PCR results, with expression receding over time (Figs 2B and 2C). Whereas expression of *MT-1* transcripts was mostly lost after 48 hours of continuous cadmium exposure in non-differentiated cell cultures (Fig 2B with independent cell line repeats in supplementary Figs S1 and S2), MT-1 subfamily transcript expression was still detectable in differentiated cell cultures after 72 hours exposure (Fig 2C; with independent repeats in supplementary Figs S3 and S4).

Irrespective of differentiation state and the presence or absence of cadmium, *MT-2A* transcript expression was constitutively high, whilst *MT-3* and *MT-4* transcripts were invariably absent. Based on this, the *MT-2A*, *MT-3* and *MT-4* genes were not further studied. By contrast, the strong induction of the *MT-1A*, *-1G*, *-1H* and *-1M* paralogues, which was consistent following cadmium-exposure in three independent NHU cell lines, was further investigated for specificity. As the RT-PCR results demonstrated a striking on/off transcriptional response of the MT isoforms to cadmium exposure, it was decided to continue with this approach, as quantitative PCR would likely not have added anything to the data.




Figure 2. Baseline and cadmium-induced MT transcript expression by NHU cells in vitro. (A) Next generation sequencing data showing baseline MT isoform transcription in non-differentiated and differentiated NHU cells (n=3 independent cell lines; standard deviation is shown). (B-C) MT gene expression in NHU cells assessed by RT-PCR. The total cDNA input was 1 μg and PCR reaction products were removed after 25 cycles; *GAPDH* was included as input control. See Table 1 for primer sequences and product sizes. Note that medium was changed at time T=0 only and there was no renewal of cadmium over the period. The figure shows results representative of n=3 independent NHU cell lines. Additional PCR controls included genomic DNA as a positive control and a no-template (H₂O) negative control; RT-ve samples confirmed absence of genomic contamination.

- In B, the result of exposing non-differentiated NHU cells to different concentrations of cadmium (0–20 μM) for 72 hours on MT gene expression is shown.
- In C, MT gene expression is shown in differentiated NHU cell cultures following exposure to 10 μM CdCl₂ for up to 72 hours.

2.3 Specificity of Cadmium-Induced MT Transcription

NHU cell cultures were exposed to a variety of candidate MT inducers identified from the literature.

ROS is reported as by-product of cadmium exposure [59] and we therefore sought to determine the effects of ROS on transcription of MT-1 genes. The ROS-inducing agent sulforaphane (C₆H₁₁NOS₂) and ROS-inhibitor ascorbic acid (C₆H₈O₆) were titrated against transcription of the ROS-sensitive heme oxygenase-1 (*HMOX1*) gene [74,75] to infer intracellular ROS activity (Figs 3A & 3B, respectively). Induction of expression of the four MT-1 genes in response to cadmium exposure was unaffected by 25 μg/mL ascorbic acid used to inhibit ROS, suggesting that ROS was not responsible

(Fig 3C). This conclusion was supported by the failure of 5 μ M sulforaphane to induce MT-1 expression (replicate in supplementary material, Fig S5).

Differential induction of MT-1 paralogues was examined in response to other metal ions, both essential and carcinogenic (replicates in supplementary material, Figs S6 & S7). Both zinc and nickel exposure induced *MT-1G* transcription, whereas *MT-1H* transcript expression was only minimally induced by iron, and nickel had no effect. *MT-1A* transcription was constitutively low under all conditions apart from cadmium exposure, which increased expression, and *MT-1M* transcription was specifically induced by exposure to cadmium alone.




Figure 3. Specificity of MT transcription induction by cadmium. MT gene expression was assessed by RT-PCR in NHU cells exposed to a variety of candidate inducers. The total cDNA input was 1 μg and PCR reaction products were removed after 25 cycles; *GAPDH* was included as input control. Note that medium was changed at time T=0 only and there was no renewal of treatments over the period. Additional PCR controls included genomic DNA as a positive control and a no-template (H_2O) negative control; RT-ve samples confirmed absence of genomic contamination.

- In A, non-differentiated NHU cell cultures were treated with a range of concentrations of sulforaphane ($\text{C}_6\text{H}_{11}\text{NOS}_2$) for 12 hours, and the effect on transcription of the ROS-sensitive gene *HMOX1* assessed in comparison to exposure to 10 μM CdCl_2 (n=1 independent cell line). The concentration of $\text{C}_6\text{H}_{11}\text{NOS}_2$ that induced transcription of *HMOX1* to a comparable extent to cadmium was selected.
- In B, non-differentiated NHU cell cultures were treated with a range of concentrations of ascorbic acid ($\text{C}_6\text{H}_8\text{O}_6$) for 12 hours in combination with 10 μM CdCl_2 and the effect on *HMOX1* transcription assessed. The concentration of $\text{C}_6\text{H}_8\text{O}_6$ that caused the biggest decrease in *HMOX1* transcription was selected.
- In C, NHU cell cultures (n=2 independent cell lines) were exposed to a range of candidate regulators and transcript expression was assessed for the MT-1 genes shown above to be most sensitive to cadmium induction (from Figures 2B & C). Candidate inducers tested were cadmium (10 μM CdCl_2), cadmium combined with ascorbic acid (10 μM CdCl_2 + 25 $\mu\text{g/mL}$ $\text{C}_6\text{H}_8\text{O}_6$), copper (10 μM CuSO_4), iron (10 μM FeSO_4), zinc (10 μM ZnCl_2), arsenite (2 μM NaAsO_2), nickel (200 μM NiCl_2), and sulforaphane (5 μM $\text{C}_6\text{H}_{11}\text{NOS}_2$). Essential metals were applied at equivalent concentrations to cadmium. Arsenite

and nickel were both used at their highest non-cytotoxic concentrations based on initial titration experiments (not shown).

2.4 Immunoblotting with isoform-specific antibodies

To examine if the observed induction of MT-1 gene expression translated to protein, antibodies specific to the MT-1A and MT-1M isoforms were used to perform western blotting. Control non-differentiated NHU cells lacked MT-1A and MT-1M protein expression (Fig 4A). Cadmium exposure caused induction of both MT-1A and MT-1M proteins after 72 hours (replicate in supplementary material, S8). Both proteins were also induced in cadmium-exposed differentiated NHU cells (Fig 4B; replicate in supplementary material, S9).

The specificity of MT-1A and MT-1M protein induction was examined in response to the wider range of candidate inducers. Western blotting revealed that the MT-1M isoform was induced only by cadmium exposure, supporting the RT-PCR results (Fig 4C; replicate in supplementary material, S10). MT-1A protein expression was highly induced by cadmium exposure, although low protein expression was observed under other conditions. As assessed by densitometry, only cadmium was capable of increasing MT-1A protein expression over control, resulting in a ~6-fold increase in MT-1A protein expression (Fig 4D).




Figure 5. Cadmium induction of zinc transporter-1 (*SLC30A1*) gene transcription. *SLC30A1* gene transcript expression was assessed by RT-PCR, with PCR reaction products removed after 25 cycles. PCR controls included genomic DNA as a positive control and a no-template (H₂O) negative control. Total cDNA input was 1 µg with GAPDH used as an input loading control; RT-ve samples confirmed the absence of genomic contamination. For differentiated NHU cells, differentiation was confirmed by assessment of TEER as >1000 Ω.cm² (see supplementary materials, Table 1).

- A: NHU cells in non-differentiated and differentiated states were maintained in control medium or with 10 µM CdCl₂ for up to 72 hours. Note that medium was changed at time T=0 and there was no renewal of the cadmium over the period. The figure shows representative results from n=3 (non-differentiated) and n=1 (differentiated) independent NHU cell lines.
- B: RT-PCR of NHU cells in a non-differentiated state maintained in standard medium (control) or with 10 µM CdCl₂ for up to 24 hours prior to the experiment ('pre-exposure'), whereupon cadmium was removed from the medium (time point 0) and culture continued for a further 48 hours.
- C: RT-PCR of NHU cells in a differentiated state maintained in standard medium (control) or with 10 µM CdCl₂ for up to 3 days prior to the experiment ('pre-exposure'), whereupon cadmium was removed from the medium (time point 0) and culture continued for up to 11 days.

3. Discussion

To the authors' knowledge, this is the first study to investigate if cadmium exposure affects urothelial tight barrier function. Previous studies have examined the effect of cadmium exposure on renal [76] and bronchial [77] epithelia, with both studies reporting a decrease or complete collapse of barrier function. By contrast, the results from this study showed that urothelial barrier function was retained and even tightened. This may reflect the type of epithelium being tested, as urothelial cells are known to form one of the tightest epithelial barriers in the human body and thus may be unique in their resistance to cadmium. Although cadmium did not compromise urothelial barrier function, our results found that apical exposure induced expression of MT-1 genes in underlying NHU cells and using ICP-OES, cadmium was detected in differentiated urothelial cell sheets. Taken together, these results indicate that the urothelium remains intact and may even mount a protective response to cadmium in terms of tight junction tightening, yet the heavy metal is able to penetrate the urothelial barrier.

Also for the first time, we describe specific MT gene expression by normal human urothelium. Our results are consistent with previous reports in other tissues that MT-1 is the inducible subfamily [22,40,78], whereas MT-2A is the most widely expressed isoform, accounting for up to 50 % total MT expression in humans [6,79]. In agreement with the consensus that MT-3 is neural-restricted [80], we found no agents that could induce MT-3 transcription in urothelial cells. As an anomaly, one group has previously suggested a link between heavy metal exposure, MT-3 induction and urothelial carcinogenesis based on high MT-3 expression in malignant bladder cancer [81] and supported by in vitro studies in cadmium-transformed UROtsa cells [82,83]. However, we were not able to replicate those findings in our normal cell system.

Of the MT-1 genes, transcription of MT-1F and MT-1G has previously been described as constitutive in human umbilical vein epithelial cells (HUVEC) under baseline conditions [42]. Both these genes exhibited low basal but inducible expression in NHU cells, therefore it cannot be certain whether the expression differences between tissues are constitutive, or due to inducers present in the culture medium. Whereas we found the majority of MT-1 paralogues to be inducible by cadmium exposure, transcript expression was transient, presumably due to sequestration leaving fewer free cadmium ions to maintain induction. By contrast, expression of MT-1 proteins was more stable and in line with the sequestering nature of the formed MT-cadmium complex. Previously, MT-1 protein isoform detection has been performed using mass-spectrometry [41], but the demonstrated

availability of specific antibodies now opens the door to detection using immunochemical approaches.

Exposure of proliferating NHU cell cultures to a range of divalent metal ions revealed differential and inducer-specific induction of MT-1 isoforms. For example, zinc ions induced strong transcription of *MT-1G*, but not *MT-1A* genes, whereas nickel ions caused *MT-1G* expression exclusively. Inducer-specific expression of MT-1 genes has been noted in other cell types [34,44–47], supporting the hypothesis that individual isoforms have very selective metal ion sequestering functions [5,6,22,39,40,84]. Western blotting revealed that cadmium was the most potent inducer of MT-1A protein expression, whereas MT-1M protein expression was highly specific to cadmium, revealing the potential of both as biomarkers of cadmium exposure. Neither arsenic nor nickel induced MT-1A or MT-1M expression, further demonstrating the specificity of MT-1 genes to differentiate between different non-genotoxic carcinogenic metals [85,86].

Alongside a pathophysiological role in sequestering carcinogenic metals, the MTs are considered to contribute to the normal homeostasis of zinc, which, as a cofactor involved in many key cellular processes [56], is under tight control. MT sequestration and zinc transporter efflux coordinated by a common transcription factor *MTF-1* [87] is thought to regulate the availability of zinc [88–91]. Changes in intracellular zinc concentration have been associated with tumour growth and progression [92]. The displacement of zinc from the proteome by cadmium may affect the intracellular concentration and/or availability of zinc ions and can substitute and destabilise the functional sites of zinc-containing proteins, such as zinc-finger transcription factors, changing the character and/or rendering them non-functional [54,55].

Preliminary investigation into the effect of cadmium exposure on zinc homeostasis in normal urothelial cells revealed an upregulation of the zinc transporter-1 (*SLC30A1*) gene transcript in non-differentiated NHU cells. *SLC30A1* upregulation was also observed in cadmium-exposed differentiated NHU cell sheets possessing a functional barrier, further suggesting that cadmium can penetrate an intact urothelial barrier. Such results agree with a previous study using the human hepatic HepG2 cell line, which demonstrated increased *SLC30A1* protein expression and localization at the cell membrane after acute cadmium exposure [93]. A later study showed cadmium exposure resulted in a 93% increase in the intracellular labile zinc concentration, suggesting a large displacement of zinc ions from the proteome, possibly due to substitution by cadmium [94].

MT expression is often seen as a ‘double-edged sword’ as on the one hand, it functions to protect the cell, but by the same mechanisms can also facilitate malignant events [6,22,95,96]. MTs may contribute to cell survival by increasing resistance to ROS-induced apoptosis [97] and increasing cellular proliferation [32]. Cadmium exposure can result in inhibition of DNA repair [98], which coupled with increased cellular protection *via* cadmium-induced MT expression, increases the probability of deleterious cells surviving and passing on defects to their progeny [96]. The ability of MT to counteract ROS could also play a role in chemotherapy resistance, and high expression of MTs has been correlated with treatment resistance in bladder cancer [99,100]. Specifically, after radical surgery and adjuvant chemotherapy, 100% patients with high tumour MT expression progressed within nine months, whereas in patients with low MT expression, only 65% had progressed after five years [101].

Our study supports a concordant induction of MT isoforms and *SLC30A1* transcription in response to cadmium exposure. Whereas this does not directly contradict hypotheses that cadmium exposure increases cellular zinc concentration or that cellular zinc homeostasis is maintained through the cooperative regulation of MT and zinc transporters [39], it does proffer a more direct relationship with cadmium responsible for regulating *SLC30A1* expression. This may reveal new insight as to the role of cadmium in (bladder) cancer, where previously reported *SLC30A1* and MT changes may reflect increased concentrations of intracellular cadmium rather than zinc. Our demonstration of differential MT-1 gene paralogue induction by zinc and cadmium should help design future (e.g. knockout) experiments to clarify the respective roles. Further experiments might also directly quantify intracellular zinc in NHU cells after cadmium exposure and determine the consequences of cadmium on zinc homeostasis and dysregulated cadmium-substituted proteins.

4. Materials and Methods

4.1 NHU cell culture and exposure to cadmium and other agents

Normal human urothelial (NHU) cells were maintained *in vitro* as non-immortalised cell lines, as detailed elsewhere [57,102]. For routine culture, NHU cells were grown as adherent monolayers on Primaria™ plasticware (BD Biosciences) in low calcium [0.09 mM] keratinocyte serum-free medium (KSFM) containing bovine pituitary extract and recombinant epidermal growth factor (Life Technologies) supplemented with 30 ng/ml cholera toxin (KSFMc). NHU cell lines were sub-cultured by trypsinisation at just-confluence and used in experiments between passages 3-5.

For cadmium exposure, medium was replaced with fresh medium containing 10 µM cadmium chloride (CdCl₂). This concentration was selected after preliminary titration for toxicity (Figs 1A & 1B). For other treatment agents, concentrations were selected following initial titration and target gene expression assessment (Figs 3A & 3B).

NHU cell lines retain the capacity to differentiate to form a functional tight barrier epithelium (as described in [58]). Differentiation was induced by switching NHU cells into medium supplemented with 5% adult bovine serum for 5 days before sub-culture onto semi-permeable ThinCert™ (Greiner Bio-One) membranes with a 0.4 µm pore size. After 24 hours, the exogenous calcium (Ca²⁺) concentration was increased to 2 mM (near physiological) and cultures were maintained for a further 7-9 days to develop a tight barrier. For cadmium exposure of differentiated NHU cell cultures, medium was removed from the apical chamber after establishment of a barrier >1000 Ω.cm² (see below) and replaced with fresh medium supplemented with 10 µM CdCl₂, in order to mimic apical exposure. RNA and protein were then harvested from these membranes for further analysis.

4.2 Measurement of transepithelial electrical resistance

The barrier function of differentiated NHU cell sheets was assessed in triplicate cultures by measuring the transepithelial electrical resistance (TEER) using an EVOM™ voltohmmeter (World Precision Instruments), as described [103]. A blank (no cell) membrane measurement was subtracted from each TEER reading.

4.3 MT transcript abundance quantification by next generation sequencing

mRNA-seq data for three donor-matched NHU cultured non-differentiated and differentiated samples were previously generated by our group [104]. Sequencing reads were 'pseudoaligned' to the Ensembl v.91 human transcriptome (GRCh38.p10) using kallisto v0.44.0 [105] and relative gene abundance was calculated as transcripts per million (TPM) following gene-level aggregation with tximport v1.8.0 [106]. Differentiation-associated expression changes in the MT gene family were detected by a differential-expression analysis conducted by sleuth [107] accounting for matched-donor samples. Differentially-expressed genes are reported with their log₂ transformed fold change (log₂FC) and 'q' value (Benjamini-Hochberg correction).

4.4 Reverse transcriptase-polymerase chain reaction (RT-PCR)

RT-PCR was performed to observe actual patterns of MT isoform induction (rather than relative change). RNA was extracted from cells using TRIzol® (ThermoFisher Scientific) and treated with a DNA-free™ kit (Ambion). cDNA synthesis was performed on 1 µg RNA with random hexamers and the SuperScript®II First-Strand Synthesis System (Life Technologies). PCR primers were designed specifically to detect all known splice variants for each MT-1 isoform gene, with GAPDH used as the internal transcript control [108]. Primer sequences and optimised PCR conditions are provided in Table 1. PCR was carried out in a T100 thermal cycler (Bio-Rad) using 25 reaction cycles. Controls consisted of genomic DNA (gDNA as template positive control), water (no template control) and no

reverse transcriptase (gDNA negative control). PCR products were separated on 2 % (w/v) agarose gels, stained using SYBR® Safe DNA gel stain (Invitrogen) and visualised on a Gene Genius Gel Imaging System (Syngene).

Table 1: Details of primers used for experiments.

Target Gene	Forward or Reverse	Sequence (5'-3')	Product Size (bp)
GAPDH	Forward	CAAGGTCATCCATGACAACCTTG	90
GAPDH	Reverse	GGGCCATCCACAGTCTTCTG	90
HMOX1	Forward	CCAGCAACAAAGTGCAAGATTC	102
HMOX1	Reverse	GTGTAAGGACCCATCGGAGAAG	102
MT-1A	Forward	CTCGAAATGGACCCCAACT	219
MT-1A	Reverse	ATATCTTCGAGCAGGGCTGTC	219
MT-1B	Forward	GGAAGTCCAGGCTTGTCTTGG	77
MT-1B	Reverse	TTGCAGGAGGTACATTTG	77
MT-1E	Forward	TGCGCCGGCTCCTGCAAGTC	118
MT-1E	Reverse	ATGCCCTTTGACAGACGCAGC	118
MT-1F	Forward	CCTGCACCTGCGCTGGTTCC	110
MT-1F	Reverse	ACAGCCCTGGGCACACTTGC	110
MT-1G	Forward	CTTCTCGCTTGGAAGTCTA	309
MT-1G	Reverse	AGGGGTCAAGATTGTAGCAA	309
MT-1H	Forward	CCTCTTCTTCTCGCTTGG	317
MT-1H	Reverse	GCAAATGAGTCGGAGTTGTAG	317
MT-1M	Forward	CTAGCAGTCGCTCCATTTATCG	180
MT-1M	Reverse	CAGCTGCAGTTCTCCAACGT	180
MT-1X	Forward	GGACCCAACTGCTCCTGCTC	151
MT-1X	Reverse	TTTGCAGATGCAGCCCTGGGC	151
MT-2A	Forward	CCGACTCTAGCCGCTCTT	259
MT-2A	Reverse	GTGGAAGTCGCGTTCTTTACA	259
MT-3	Forward	AGTGCAGGGATGCAAATG	98

MT-3	Reverse	GCCTTTGCACACACAGTCCTT	98
SLC30A1	Forward	GCATCAGTTTATGAGGCTGGTCCT	352
SLC30A1	Reverse	CAGGCTGAATGGTAGTAGCGTGAA	352

4.5 Western blotting

NHU cell cultures were lysed into electrophoresis sample buffer containing protease inhibitors and sonicated. Twenty µg protein was resolved on 4-12% Bis-Tris NuPage™ polyacrylamide gels (Invitrogen) in 2-(N-morpholino) ethanesulfonic acid (MES) buffer and electro-transferred onto polyvinylfluoride membranes (Millipore). Membranes were blocked with Odyssey® blocking buffer (LI-COR®), incubated with primary antibodies for 16 h at 4°C and bound antibody detected using Alexa Fluor® 680-conjugated anti-mouse secondary antibody (Invitrogen) or an IRDye 800-conjugated anti-rabbit secondary antibody (Tebu-Bio). Antibody binding was visualised using an Odyssey® Sa Infrared Imaging System (LI-COR®). Protein quantification was performed using Odyssey® Image Studio™ software v5.0 (LI-COR®). Details of antibodies are given Tables 2 and 3.

Table 2: Details of primary antibodies used for experiments.

Antigen	Clone	Host	Supplier	Dilution	Molecular Weight (kDa)
Beta-actin	A5441	Mouse	Sigma Aldrich	1:10 000 (WB)	42
MT-1A	B01P	Mouse	Abnova	1:750 (WB)	6
MT-1M	17281-AP	Rabbit	ProteinTech	1 µg/mL (WB)	6

Table 3: Details of secondary antibodies used for experiments.

Antigen	Conjugate	Host	Supplier	Application
Anti-mouse IgG	Alexa 680	Goat	Life Technologies	WB
Anti-rabbit IgG	Alexa 800	Goat	Life Technologies	WB

5. Conclusions

MT-1 isoform expression has been characterised in normal human urothelium for the first time, and a unique expression profile described with the use of isoform-specific antibodies. Individual MT-1 genes demonstrated inducer-specific expression and two paralogues with cadmium-specific or -selective induction were identified as candidate biomarkers of cadmium exposure. With the potential for cadmium to interfere and substitute in the homeostatic regulation of zinc, new approaches are proposed for understanding cadmium-induced non-genotoxic carcinogenesis.

Supplementary Materials: Supplementary materials can be found at www.mdpi.com/xxx/s1.

Author Contributions: Conceptualization, R.M., M.H., J.C. and J.S.; methodology, R.M., M.H., A.M. and J.C.; software, R.M. and A.M.; validation, R.M. and J.S.; formal analysis, R.M. and A.M.; investigation, R.M.; resources, M.H., J.C. and J.S.; data curation, R.M. and J.S.; writing—original draft preparation, R.M.; writing—review and editing, A.M., J.C. and J.S.; visualization, R.M. and J.S.; supervision, J.S.; project administration, R.M. and J.S.; funding acquisition, J.C. and J.S.

Funding: This work was funded by Yorkshire Cancer Research (YCR) through a studentship award to R.M. Additional support was provided by York Against Cancer (YAC).

Conflicts of Interest: The authors declare no conflict of interest.


Abbreviations

HMOX1	Heme oxygenase-1
MT	Metallothionein
NHU	Normal human urothelial
SLC30A1	Solute carrier family A member 1
TEER	Trans-epithelial electrical resistance


Appendix A

Supplementary Table 1: TEER readings from different NHU cell lines used for experiments. Each reading is an average of three technical replicates. A TEER reading $>0.5 \text{ k}\Omega\cdot\text{cm}^2$ is considered to reflect a functional urothelial barrier.


Cell Line	Figure	Time Point	TEER ($\text{k}\Omega\cdot\text{cm}^2$)	
			Control	Cadmium
Y1456	1B, Suppl.	12h	3.54	4.88
		24h	3.58	3.96
		48h	4.63	2.14
		72h	3.78	4.09
Y1493	Suppl.	24h	2.00	2.65
		48h	3.20	2.99
		72h	2.27	2.30
Y1426	4C, Suppl.	72h	3.33	4.43




Supplementary Figure 1: RT-PCR showing MT isoform transcription in proliferating NHU cells exposed to cadmium (experimental replicate from Fig 2B). Non-differentiated NHU cells were exposed to 10 μM CdCl₂ for up to 48 hours. The total cDNA input was 1 μg and PCR reaction products were removed after 25 cycles.



Supplementary Figure 2: RT-PCR showing MT isoform transcription in proliferating NHU cells exposed to cadmium (experimental replicate from Fig 2B). Non-differentiated NHU cells were exposed to 10 μ M CdCl₂ for up to 12 hours. The total cDNA input was 1 μ g and PCR reaction products were removed after 25 cycles.




Supplementary Figure 3: RT-PCR showing MT isoform transcription in cadmium-exposed differentiated NHU cell sheets that demonstrated a functional barrier (experimental replicate from Fig 2C). NHU cells were differentiated and exposed to 10 μ M CdCl₂ for up to 72 hours. Differentiation was confirmed using TEER readings and expression of KRT13. The total cDNA input was 1 μ g and PCR reaction products were removed after 25 cycles.




Supplementary Figure 4: RT-PCR showing MT isoform transcription in cadmium-exposed differentiated NHU cell sheets that demonstrated a functional barrier (experimental replicate from Fig 2C). NHU cells were differentiated and exposed to 10 μ M CdCl₂ for up to 72 hours. Differentiation


was confirmed using TEER readings and expression of ZO-1. The total cDNA input was 1 µg and PCR reaction products were removed after 25 cycles.




Supplementary Figure 5: RT-PCR showing the effects of ROS on MT isoform transcription in NHU cells (experimental replicate from Fig 3C). The chemical Sulforaphane (C₆H₁₁NOS₂) was used to induce ROS, having been titrated to a concentration that mimicked the levels of cadmium-induced ROS. Non-differentiated NHU cells were treated with either 10 µM CdCl₂ or 5 µM C₆H₁₁NOS₂ for 12 hours. The total cDNA input was 1 µg and PCR reaction products were removed after 25 cycles.




Supplementary Figure 6: RT-PCR showing the effects of essential metal exposure on MT-1 isoform transcription in NHU cells (experimental replicate from Fig 3C). Non-differentiated NHU cells were exposed to either 10 μ M CdCl₂, 10 μ M CuSO₄, 10 μ M FeSO₄, or 10 μ M ZnCl₂ for 12 hours. The total cDNA input was 1 μ g and PCR reaction products were removed after 25 cycles.




Supplementary Figure 7: RT-PCR showing the effects of exposure to the carcinogenic metals arsenite and nickel on MT-1 isoform transcription in NHU cells (experimental replicate from Fig 3C). Non-differentiated NHU cells were exposed to a range of concentrations of arsenite (0.25 μ M – 2 μ M; NaAsO₂) and nickel (25 μ M – 200 μ M; NiCl₂) for 12 hours. The total cDNA input was 1 μ g and PCR reaction products were removed after 25 cycles.




Supplementary Figure 8: Western blots showing MT-1A and MT-1M protein expression in non-differentiated NHU cells exposed to cadmium (experimental replicate from Fig 4A). Non-differentiated NHU cells (n=3) were exposed to 10 μ M CdCl₂ for 72 hours and protein expression of (A) MT-1A and (B) MT-1M determined using novel, isoform-specific antibodies. β -actin protein expression was used as a loading control.



Supplementary Figure 9: Western blots demonstrating MT-1A and 1M protein expression in differentiated NHU cells with functional barriers that were exposed to cadmium (experimental replicate from Fig 4B). NHU cells were stimulated to differentiate and form a functional barrier, before exposure to 10 μM CdCl_2 . (A) MT-1A protein expression was assessed at multiple time-points to ensure exposure time was adequate for protein translation in differentiated NHU cells. (B) Western blots showing MT-1A and MT-1M protein expression and (C) MT-1A protein expression in differentiated NHU cells exposed to cadmium for 72 hours. β -actin protein expression was used as a loading control.



Supplementary Figure 10: Western blot showing the specificity of cadmium-induced MT-1A and MT-1M isoform protein expression in NHU cells (experimental replicate from Fig 4C). Non-differentiated NHU cells were exposed to a range of potential inducers for 72 hours. Candidate inducers were cadmium (10 μM CdCl_2), copper (10 μM CuSO_4), iron (10 μM FeSO_4), zinc (10 μM ZnCl_2), arsenite (2 μM NaAsO_2), nickel (200 μM NiCl_2), and sulforaphane (5 μM $\text{C}_6\text{H}_{11}\text{NOS}_2$). Cadmium in combination with ascorbic acid (25 $\mu\text{g/mL}$ $\text{C}_6\text{H}_8\text{O}_6$) was also included, to support the RT-PCR data demonstrating that inhibition of cadmium-induced ROS did not inhibit cadmium-induced MT expression (Fig 3C). β -actin protein expression was used as a loading control.



Supplementary Figure 11: Effect of cadmium exposure on zinc transporter-1 (SLC30A1) transcription (experimental replicate from Fig 5B). RT-PCR of SLC30A1 gene transcription in non-differentiated NHU cells exposed to 10 µM CdCl₂ for 3 or 7 days. Note that medium was changed at time T=0 and that for 3 day exposure there was no renewal of the cadmium by medium change over the period. For 7 day exposure, cadmium-containing medium was renewed on day 4. The total cDNA input was 1 µg and PCR reaction products were removed after 25 cycles.

References

1. Tchounwou, P.B.; Yedjou, C.G.; Patlolla, A.K.; Sutton, D.J. Heavy Metals Toxicity and the Environment. *EXS* **2012**, *101*, 133–164.
2. Feki-Tounsi, M.; Hamza-Chaffai, A. Cadmium as a possible cause of bladder cancer: a review of accumulated evidence. *Environ Sci Pollut Res* **2014**, *21*, 10561–10573.
3. Waalkes, M.P. Cadmium carcinogenesis. *Mutat. Res.* **2003**, *533*, 107–120.
4. Agency for Toxic Substances and Disease Registry Toxicological profile for cadmium Available online: <https://www.atsdr.cdc.gov/toxprofiles/tp.asp?id=48&tid=15> (accessed on Sep 14, 2016).
5. Coyle, P.; Philcox, J.C.; Carey, L.C.; Rofe, A.M. Metallothionein: the multipurpose protein. *Cell. Mol. Life Sci.* **2002**, *59*, 627–647.
6. Sigel, A.; Sigel, H.; Sigel, R.K.O. *Metallothioneins and Related Chelators*; Metal Ions in Life Sciences; RSC Publishing: Cambridge, 2009; Vol. 5;.
7. Klaassen, C.D.; Choudhuri, S.; McKim, J.M.; Lehman-McKeeman, L.D.; Kershaw, W.C. In vitro and in vivo studies on the degradation of metallothionein. *Environ Health Perspect* **1994**, *102*, 141–146.
8. Kellen, E.; Zeegers, M.P.; Hond, E.D.; Buntinx, F. Blood cadmium may be associated with bladder carcinogenesis: the Belgian case-control study on bladder cancer. *Cancer Detect. Prev.* **2007**, *31*, 77–82.
9. Wolf, C.; Strenziok, R.; Kyriakopoulos, A. Elevated metallothionein-bound cadmium concentrations in urine from bladder carcinoma patients, investigated by size exclusion chromatography-inductively coupled plasma mass spectrometry. *Anal. Chim. Acta* **2009**, *631*, 218–222.
10. Feki-Tounsi, M.; Olmedo, P.; Gil, F.; Khelifi, R.; Mhiri, M.-N.; Rebai, A.; Hamza-Chaffai, A. Cadmium in blood of Tunisian men and risk of bladder cancer: interactions with arsenic exposure and smoking. *Environ Sci Pollut Res Int* **2013**, *20*, 7204–7213.
11. Chang, C.-H.; Liu, C.-S.; Liu, H.-J.; Huang, C.-P.; Huang, C.-Y.; Hsu, H.-T.; Liou, S.-H.; Chung, C.-J. Association between levels of urinary heavy metals and increased risk of urothelial carcinoma. *Int. J. Urol.* **2016**, *23*, 233–239.
12. Achanzar, W.E.; Diwan, B.A.; Liu, J.; Quader, S.T.; Webber, M.M.; Waalkes, M.P. Cadmium-induced Malignant Transformation of Human Prostate Epithelial Cells. *Cancer Res* **2001**, *61*, 455–458.

13. Takiguchi, M.; Achanzar, W.E.; Qu, W.; Li, G.; Waalkes, M.P. Effects of cadmium on DNA-(Cytosine-5) methyltransferase activity and DNA methylation status during cadmium-induced cellular transformation. *Experimental Cell Research* **2003**, *286*, 355–365.
14. Lei, Y.-X.; Wei, L.; Wang, M.; Wu, G.-R.; Li, M. Malignant transformation and abnormal expression of eukaryotic initiation factor in bronchial epithelial cells induced by cadmium chloride. *Biomed. Environ. Sci.* **2008**, *21*, 332–338.
15. Sens, D.A.; Park, S.; Gurel, V.; Sens, M.A.; Garrett, S.H.; Somji, S. Inorganic Cadmium- and Arsenite-Induced Malignant Transformation of Human Bladder Urothelial Cells. *Toxicol. Sci.* **2004**, *79*, 56–63.
16. Kreft, M.E.; Hudoklin, S.; Jezernik, K.; Romih, R. Formation and maintenance of blood–urine barrier in urothelium. *Protoplasma* **2010**, *246*, 3–14.
17. Caldwell, J.; Gardner, I.; Swales, N. An Introduction to Drug Disposition: The Basic Principles of Absorption, Distribution, Metabolism, and Excretion. *Toxicol Pathol* **1995**, *23*, 102–114.
18. Krause, M.; Rak-Raszewska, A.; Pietilä, I.; Quaggin, S.E.; Vainio, S. Signaling during Kidney Development. *Cells* **2015**, *4*, 112–132.
19. Margoshes, M.; Vallee, B.L. A Cadmium Protein from Equine Kidney Cortex. *J. Am. Chem. Soc.* **1957**, *79*, 4813–4814.
20. Kägi, J.H.; Schäffer, A. Biochemistry of metallothionein. *Biochemistry* **1988**, *27*, 8509–8515.
21. Hunt, C.T.; Boulanger, Y.; Fesik, S.W.; Armitage, I.M. NMR analysis of the structure and metal sequestering properties of metallothioneins. *Environ Health Perspect* **1984**, *54*, 135–145.
22. Capdevila, M.; Bofill, R.; Palacios, Ò.; Atrian, S. State-of-the-art of metallothioneins at the beginning of the 21st century. *Coordination Chemistry Reviews* **2012**, *256*, 46–62.
23. Dalton, T.; Fu, K.; Palmiter, R.D.; Andrews, G.K. Transgenic mice that overexpress metallothionein-I resist dietary zinc deficiency. *J. Nutr.* **1996**, *126*, 825–833.
24. Kelly, E.J.; Quaife, C.J.; Froelick, G.J.; Palmiter, R.D. Metallothionein I and II protect against zinc deficiency and zinc toxicity in mice. *J. Nutr.* **1996**, *126*, 1782–1790.
25. Lee, D.K.; Geiser, J.; Dufner-Beattie, J.; Andrews, G.K. Pancreatic metallothionein-I may play a role in zinc homeostasis during maternal dietary zinc deficiency in mice. *J. Nutr.* **2003**, *133*, 45–50.
26. Penkowa, M.; Cáceres, M.; Borup, R.; Nielsen, F.C.; Poulsen, C.B.; Quintana, A.; Molinero, A.; Carrasco, J.; Florit, S.; Giralt, M.; et al. Novel roles for metallothionein-I + II (MT-I + II) in defense responses, neurogenesis, and tissue restoration after traumatic brain injury: Insights from global gene expression profiling in wild-type and MT-I + II knockout mice. *Journal of Neuroscience Research* **2006**, *84*, 1452–1474.
27. Lazo, J.S.; Kondo, Y.; Dellapiazza, D.; Michalska, A.E.; Choo, K.H.; Pitt, B.R. Enhanced sensitivity to oxidative stress in cultured embryonic cells from transgenic mice deficient in metallothionein I and II genes. *J. Biol. Chem.* **1995**, *270*, 5506–5510.

28. Karin; Haslinger, A.; Holtgreve, H.; Richards, R.I.; Krauter, P.; Westphal, H.M.; Beato, M. Characterization of DNA sequences through which cadmium and glucocorticoid hormones induce human metallothionein-IIA gene. *Nature* **1984**, *308*, 513–519.
29. Schulkens, I.A.; Castricum, K.C.M.; Weijers, E.M.; Koolwijk, P.; Griffioen, A.W.; Thijssen, V.L. Expression, regulation and function of human metallothioneins in endothelial cells. *J. Vasc. Res.* **2014**, *51*, 231–238.
30. Yap, X.; Tan, H.-Y.; Huang, J.; Lai, Y.; Yip, G.W.-C.; Tan, P.-H.; Bay, B.-H. Over-expression of metallothionein predicts chemoresistance in breast cancer. *J. Pathol.* **2009**, *217*, 563–570.
31. Liu, Z.-M.; Hasselt, C.A. van; Song, F.-Z.; Vlantis, A.C.; Cherian, M.G.; Koropatnick, J.; Chen, G.G. Expression of functional metallothionein isoforms in papillary thyroid cancer. *Molecular and Cellular Endocrinology* **2009**, *302*, 92–98.
32. Ioachim, E.E.; Charchanti, A.V.; Stavropoulos, N.E.; Athanassiou, E.D.; Michael, M.C.; Agnantis, N.J. Localization of metallothionein in urothelial carcinoma of the human urinary bladder: an immunohistochemical study including correlation with HLA-DR antigen, p53, and proliferation indices. *Anticancer Res.* **2001**, *21*, 1757–1761.
33. Jin, R.; Chow, V.T.-K.; Tan, P.-H.; Dheen, S.T.; Duan, W.; Bay, B.-H. Metallothionein 2A expression is associated with cell proliferation in breast cancer. *Carcinogenesis* **2002**, *23*, 81–86.
34. Varshney, U.; Jahroudi, N.; Foster, R.; Gedamu, L. Structure, organization, and regulation of human metallothionein IF gene: differential and cell-type-specific expression in response to heavy metals and glucocorticoids. *Mol. Cell. Biol.* **1986**, *6*, 26–37.
35. Boonprasert, K.; Ruengweerayut, R.; Aunpad, R.; Satarug, S.; Na-Bangchang, K. Expression of metallothionein isoforms in peripheral blood leukocytes from Thai population residing in cadmium-contaminated areas. *Environmental Toxicology and Pharmacology* **2012**, *12*, S1382–6689.
36. Mita, M.; Satoh, M.; Shimada, A.; Okajima, M.; Azuma, S.; Suzuki, J.S.; Sakabe, K.; Hara, S.; Himeno, S. Metallothionein is a crucial protective factor against *Helicobacter pylori*-induced gastric erosive lesions in a mouse model. *Am. J. Physiol. Gastrointest. Liver Physiol.* **2008**, *294*, G877–884.
37. Kägi, J.H.; Kojima, Y. Chemistry and biochemistry of metallothionein. *Experientia Suppl.* **1987**, *52*, 25–61.
38. Irvine, G.W.; Pinter, T.B.J.; Stillman, M.J. Defining the metal binding pathways of human metallothionein 1a: balancing zinc availability and cadmium seclusion. *Metallomics* **2016**, *8*, 71–81.
39. Kimura, T.; Kambe, T. The Functions of Metallothionein and ZIP and ZnT Transporters: An Overview and Perspective. *International Journal of Molecular Sciences* **2016**, *17*, 336.

40. Miles, A.T.; Hawksworth, G.M.; Beattie, J.H.; Rodilla, V. Induction, Regulation, Degradation, and Biological Significance of Mammalian Metallothioneins. *Critical Reviews in Biochemistry and Molecular Biology* **2000**, *35*, 35–70.
41. Mehus, A.A.; Muhonen, W.W.; Garrett, S.H.; Somji, S.; Sens, D.A.; Shabb, J.B. Quantitation of Human Metallothionein Isoforms: A Family of Small, Highly Conserved, Cysteine-rich Proteins. *Mol Cell Proteomics* **2014**, *13*, 1020–1033.
42. Conway, D.E.; Lee, S.; Eskin, S.G.; Shah, A.K.; Jo, H.; McIntire, L.V. Endothelial metallothionein expression and intracellular free zinc levels are regulated by shear stress. *Am J Physiol Cell Physiol* **2010**, *299*, C1461–C1467.
43. Jahroudi, N.; Foster, R.; Price-Haughey, J.; Beitel, G.; Gedamu, L. Cell-type specific and differential regulation of the human metallothionein genes. Correlation with DNA methylation and chromatin structure. *J. Biol. Chem.* **1990**, *265*, 6506–6511.
44. Miura, N.; Koizumi, S. Heavy metal responses of the human metallothionein isoform genes. *Journal of the Pharmaceutical Society of Japan* **2007**, *127*, 665–673.
45. Richards, R.I.; Heguy, A.; Karin, M. Structural and functional analysis of the human metallothionein-IA gene: differential induction by metal ions and glucocorticoids. *Cell* **1984**, *37*, 263–272.
46. Selvaraj, A.; Balamurugan, K.; Yepiskoposyan, H.; Zhou, H.; Egli, D.; Georgiev, O.; Thiele, D.J.; Schaffner, W. Metal-responsive transcription factor (MTF-1) handles both extremes, copper load and copper starvation, by activating different genes. *Genes Dev* **2005**, *19*, 891–896.
47. Sims, H.I.; Chirn, G.-W.; Marr, M.T. Single nucleotide in the MTF-1 binding site can determine metal-specific transcription activation. *PNAS* **2012**, *109*, 16516–16521.
48. Sadhu, C.; Gedamu, L. Regulation of human metallothionein (MT) genes. Differential expression of MTI-F, MTI-G, and MTII-A genes in the hepatoblastoma cell line (HepG2). *J. Biol. Chem.* **1988**, *263*, 2679–2684.
49. Lehman-McKeeman, L.D.; Andrews, G.K.; Klaassen, C.D. Mechanisms of regulation of rat hepatic metallothionein-I and metallothionein-II levels following administration of zinc. *Toxicology and Applied Pharmacology* **1988**, *92*, 1–9.
50. Klaassen, C.D.; Lehman-McKeeman, L.D. Regulation of the isoforms of metallothionein. *Biol Trace Elem Res* **1989**, *21*, 119–129.
51. Kim, J.-H.; Wang, S.-Y.; Kim, I.-C.; Ki, J.-S.; Raisuddin, S.; Lee, J.-S.; Han, K.-N. Cloning of a river pufferfish (*Takifugu obscurus*) metallothionein cDNA and study of its induction profile in cadmium-exposed fish. *Chemosphere* **2008**, *71*, 1251–1259.
52. Jasani, B.; Schmid, K.W. Significance of metallothionein overexpression in human tumours. *Histopathology* **1997**, *31*, 131–136.
53. Chaney, R.L. Cadmium and Zinc. In *Trace Elements in Soils*; Wiley: New York, 2010; pp. 409–440.
54. Malgieri, G.; Zaccaro, L.; Leone, M.; Bucci, E.; Esposito, S.; Baglivo, I.; Del Gatto, A.; Russo, L.; Scandurra, R.; Pedone, P.V.; et al. Zinc to cadmium replacement in the *A. thaliana* SUPERMAN Cys₂ His₂ zinc finger induces structural rearrangements of typical DNA base determinant positions. *Biopolymers* **2011**, *95*, 801–810.

55. Tang, L.; Qiu, R.; Tang, Y.; Wang, S. Cadmium–zinc exchange and their binary relationship in the structure of Zn-related proteins: a mini review. *Metallomics* **2014**, *6*, 1313–1323.
56. Jeong, J.; Eide, D.J. The SLC39 family of zinc transporters. *Mol Aspects Med* **2013**, *34*, 612–619.
57. Southgate, J.; Hutton, K.A.; Thomas, D.F.; Trejdosiewicz, L.K. Normal human urothelial cells in vitro: proliferation and induction of stratification. *Lab. Invest.* **1994**, *71*, 583–594.
58. Cross, W.R.; Eardley, I.; Leese, H.J.; Southgate, J. A biomimetic tissue from cultured normal human urothelial cells: analysis of physiological function. *Am. J. Physiol. Renal Physiol.* **2005**, *289*, F459–468.
59. Wang, Y.; Fang, J.; Leonard, S.S.; Rao, K.M.K. Cadmium inhibits the electron transfer chain and induces reactive oxygen species. *Free Radic. Biol. Med.* **2004**, *36*, 1434–1443.
60. Heyno, E.; Klose, C.; Krieger-Liszkay, A. Origin of cadmium-induced reactive oxygen species production: mitochondrial electron transfer versus plasma membrane NADPH oxidase. *New Phytologist* **2008**, *179*, 687–699.
61. Durnam, D.M.; Palmiter, R.D. Induction of metallothionein-I mRNA in cultured cells by heavy metals and iodoacetate: evidence for gratuitous inducers. *Mol. Cell. Biol.* **1984**, *4*, 484–491.
62. Alam, J.; Smith, A. Heme-hemopexin-mediated induction of metallothionein gene expression. *J. Biol. Chem.* **1992**, *267*, 16379–16384.
63. Baird, S.K.; Kurz, T.; Brunk, U.T. Metallothionein protects against oxidative stress-induced lysosomal destabilization. *Biochem J* **2006**, *394*, 275–283.
64. Palmiter, R.D. Regulation of metallothionein genes by heavy metals appears to be mediated by a zinc-sensitive inhibitor that interacts with a constitutively active transcription factor, MTF-1. *Proc Natl Acad Sci U S A* **1994**, *91*, 1219–1223.
65. Kheradmand, F.; Nourmohammadi, I.; Modarressi, M.H.; Firoozrai, M.; Ahmadi Faghih, M.A. Differential Gene-Expression of Metallothionein 1M and 1G in Response to Zinc in Sertoli TM4 Cells. *Iran Biomed J* **2010**, *14*, 9–15.
66. Chu, A.; Foster, M.; Ward, S.; Zaman, K.; Hancock, D.; Petocz, P.; Samman, S. Zinc-induced upregulation of metallothionein (MT)-2A is predicted by gene expression of zinc transporters in healthy adults. *Genes Nutr* **2015**, *10*.
67. Chen, L.; Ma, L.; Bai, Q.; Zhu, X.; Zhang, J.; Wei, Q.; Li, D.; Gao, C.; Li, J.; Zhang, Z.; et al. Heavy metal-induced metallothionein expression is regulated by specific protein phosphatase 2A complexes. *J. Biol. Chem.* **2014**, *289*, 22413–22426.
68. Heuchel, R.; Radtke, F.; Georgiev, O.; Stark, G.; Aguet, M.; Schaffner, W. The transcription factor MTF-1 is essential for basal and heavy metal-induced metallothionein gene expression. *EMBO J* **1994**, *13*, 2870–2875.
69. Zhou, X.D.; Sens, D.A.; Sens, M.A.; Namburi, V.B.R.K.; Singh, R.K.; Garrett, S.H.; Somji, S. Metallothionein-1 and -2 Expression in Cadmium- or Arsenic-Derived Human Malignant Urothelial Cells and Tumor Heterotransplants and as a Prognostic Indicator in Human Bladder Cancer. *Toxicol. Sci.* **2006**, *91*, 467–475.

- 718 70. Irvine, G.W.; Stillman, M.J. Topographical analysis of As-induced folding of α -MT1a.
719 *Biochem. Biophys. Res. Commun.* **2013**, *441*, 208–213.
- 720 71. McMahon, R.J.; Cousins, R.J. Regulation of the zinc transporter ZnT-1 by dietary zinc.
721 *Proc. Natl. Acad. Sci. U.S.A.* **1998**, *95*, 4841–4846.
- 722 72. Holloway, A.F.; Stennard, F.A.; West, A.K. Human metallothionein gene MT1L
723 mRNA is present in several human tissues but is unlikely to produce a metallothionein
724 protein. *FEBS Lett.* **1997**, *404*, 41–44.
- 725 73. Hahn, Y.; Lee, B. Human-specific nonsense mutations identified by genome sequence
726 comparisons. *Hum. Genet.* **2006**, *119*, 169–178.
- 727 74. Ryter, S.W.; Choi, A.M.K. Heme oxygenase-1: redox regulation of a stress protein in
728 lung and cell culture models. *Antioxid. Redox Signal.* **2005**, *7*, 80–91.
- 729 75. Sarma, S.N.; Kim, Y.-J.; Song, M.; Ryu, J.-C. Induction of apoptosis in human
730 leukemia cells through the production of reactive oxygen species and activation of
731 HMOX1 and Noxa by benzene, toluene, and o-xylene. *Toxicology* **2011**, *280*, 109–
732 117.
- 733 76. Faurskov, B.; Bjerregaard, H.F. Effect of cadmium on active ion transport and
734 cytotoxicity in cultured renal epithelial cells (A6). *Toxicol In Vitro* **1997**, *11*, 717–722.
- 735 77. Cao, X.; Lin, H.; Muskhelishvili, L.; Latendresse, J.; Richter, P.; Heflich, R.H. Tight
736 junction disruption by cadmium in an in vitro human airway tissue model. *Respir. Res.*
737 **2015**, *16*, 30.
- 738 78. Thirumorthy, N.; Manisenthil Kumar, K.-T.; Shyam Sundar, A.; Panayappan, L.;
739 Chatterjee, M. Metallothionein: an overview. *World J. Gastroenterol.* **2007**, *13*, 993–
740 996.
- 741 79. Raudenska, M.; Gumulec, J.; Podlaha, O.; Sztalmachova, M.; Babula, P.; Eckschlager,
742 T.; Adam, V.; Kizek, R.; Masarik, M. Metallothionein polymorphisms in pathological
743 processes. *Metallomics* **2013**, *6*, 55–68.
- 744 80. Palmiter, R.D.; Findley, S.D.; Whitmore, T.E.; Durnam, D.M. MT-III, a brain-specific
745 member of the metallothionein gene family. *Proc Natl Acad Sci U S A* **1992**, *89*, 6333–
746 6337.
- 747 81. Sens, M.A.; Somji, S.; Lamm, D.L.; Garrett, S.H.; Slovinsky, F.; Todd, J.H.; Sens,
748 D.A. Metallothionein isoform 3 as a potential biomarker for human bladder cancer.
749 *Environ Health Perspect* **2000**, *108*, 413–418.
- 750 82. Zhou, X.D.; Sens, M.A.; Garrett, S.H.; Somji, S.; Park, S.; Gurel, V.; Sens, D.A.
751 Enhanced expression of metallothionein isoform 3 protein in tumor heterotransplants
752 derived from As+3- and Cd+2-transformed human urothelial cells. *Toxicol. Sci.* **2006**,
753 *93*, 322–330.
- 754 83. Somji, S.; Garrett, S.H.; Toni, C.; Zhou, X.D.; Zheng, Y.; Ajjimaporn, A.; Sens, M.A.;
755 Sens, D.A. Differences in the epigenetic regulation of MT-3 gene expression between
756 parental and Cd+2 or As+3 transformed human urothelial cells. *Cancer Cell Int.* **2011**,
757 *11*, 2.
- 758 84. Brazão-Silva, M.T.; Rodriguez, M.F.S.; Eisenberg, A.L.A.; Dias, F.L.; de Castro,
759 L.M.; Nunes, F.D.; Faria, P.R.; Cardoso, S.V.; Loyola, A.M.; de Sousa, S.C.O.M.

- 760 Metallothionein gene expression is altered in oral cancer and may predict metastasis
761 and patient outcomes. *Histopathology* **2015**, *67*, 358–367.
- 762 85. International Agency for Research on Cancer Beryllium, cadmium, mercury, and
763 exposures in the glass manufacturing industry. *IARC Monographs on the Evaluation*
764 *of the Carcinogenic Risks to Humans* **1993**, *58*.
- 765 86. Salnikow, K.; An, W.G.; Melillo, G.; Blagosklonny, M.V.; Costa, M. Nickel-induced
766 transformation shifts the balance between HIF-1 and p53 transcription factors.
767 *Carcinogenesis* **1999**, *20*, 1819–1823.
- 768 87. Günther, V.; Lindert, U.; Schaffner, W. The taste of heavy metals: Gene regulation by
769 MTF-1. *Biochimica et Biophysica Acta (BBA) - Molecular Cell Research* **2012**, *1823*,
770 1416–1425.
- 771 88. Kimura, T.; Itoh, N.; Andrews, G.K. Mechanisms of Heavy Metal Sensing by Metal
772 Response Element-binding Transcription Factor-1. *JOURNAL OF HEALTH*
773 *SCIENCE* **2009**, *55*, 484–494.
- 774 89. Otsuka, F. Molecular Mechanism of the Metallothionein Gene Expression Mediated
775 by Metal-Responsive Transcription Factor 1. *Journal of Health Science* **2001**, *47*, 513–
776 519.
- 777 90. Langmade, S.J.; Ravindra, R.; Daniels, P.J.; Andrews, G.K. The transcription factor
778 MTF-1 mediates metal regulation of the mouse ZnT1 gene. *J. Biol. Chem.* **2000**, *275*,
779 34803–34809.
- 780 91. Guo, L.; Lichten, L.A.; Ryu, M.-S.; Liuzzi, J.P.; Wang, F.; Cousins, R.J. STAT5-
781 glucocorticoid receptor interaction and MTF-1 regulate the expression of ZnT2
782 (Slc30a2) in pancreatic acinar cells. *Proc. Natl. Acad. Sci. U.S.A.* **2010**, *107*, 2818–
783 2823.
- 784 92. Bafaro, E.; Liu, Y.; Xu, Y.; Dempski, R.E. The emerging role of zinc transporters in
785 cellular homeostasis and cancer. *Signal Transduction and Targeted Therapy* **2017**, *2*,
786 17029.
- 787 93. Urani, C.; Melchiorretto, P.; Gribaldo, L. Regulation of metallothioneins and ZnT-1
788 transporter expression in human hepatoma cells HepG2 exposed to zinc and cadmium.
789 *Toxicology in Vitro* **2010**, *24*, 370–374.
- 790 94. Urani, C.; Melchiorretto, P.; Bruschi, M.; Fabbri, M.; Sacco, M.G.; Gribaldo, L. Impact
791 of Cadmium on Intracellular Zinc Levels in HepG2 Cells: Quantitative Evaluations
792 and Molecular Effects, Impact of Cadmium on Intracellular Zinc Levels in HepG2
793 Cells: Quantitative Evaluations and Molecular Effects. *BioMed Research*
794 *International, BioMed Research International* **2015**, *2015*, e949514.
- 795 95. Pedersen, M.Ø.; Larsen, A.; Stoltenberg, M.; Penkowa, M. The role of metallothionein
796 in oncogenesis and cancer prognosis. *Prog Histochem Cytochem* **2009**, *44*, 29–64.
- 797 96. Hart, B.A.; Potts, R.J.; Watkin, R.D. Cadmium adaptation in the lung - a double-edged
798 sword? *Toxicology* **2001**, *160*, 65–70.
- 799 97. Eneman, J.D.; Potts, R.J.; Osier, M.; Shukla, G.S.; Lee, C.H.; Chiu, J.-F.; Hart, B.A.
800 Suppressed oxidant-induced apoptosis in cadmium adapted alveolar epithelial cells
801 and its potential involvement in cadmium carcinogenesis. *Toxicology* **2000**, *147*, 215–
802 228.

98. Potts, R.J.; Bespalov, I.A.; Wallace, S.S.; Melamede, R.J.; Hart, B.A. Inhibition of oxidative DNA repair in cadmium-adapted alveolar epithelial cells and the potential involvement of metallothionein. *Toxicology* **2001**, *161*, 25–38.
99. Satoh, M.; Kloth, D.M.; Kadhim, S.A.; Chin, J.L.; Naganuma, A.; Imura, N.; Cherian, M.G. Modulation of Both Cisplatin Nephrotoxicity and Drug Resistance in Murine Bladder Tumor by Controlling Metallothionein Synthesis. *Cancer Res* **1993**, *53*, 1829–1832.
100. Wülfing, C.; van Ahlen, H.; Eltze, E.; Piechota, H.; Hertle, L.; Schmid, K.-W. Metallothionein in bladder cancer: correlation of overexpression with poor outcome after chemotherapy. *World J Urol* **2007**, *25*, 199–205.
101. Yamasaki, Y.; Smith, C.; Weisz, D.; van Huizen, I.; Xuan, J.; Moussa, M.; Stitt, L.; Hideki, S.; Cherian, M.G.; Izawa, J.I. Metallothionein expression as prognostic factor for transitional cell carcinoma of bladder. *Urology* **2006**, *67*, 530–535.
102. Southgate, J.; Masters, J.R.W.; Trejdosiewicz, L.K. Culture of Human Urothelium. In *Culture of Epithelial Cells*; John Wiley & Sons, Inc.: New York, 2002; pp. 381–399 ISBN 978-0-471-22120-3.
103. Rubenwolf, P.; Southgate, J. Permeability of differentiated human urothelium in vitro. *Methods Mol. Biol.* **2011**, *763*, 207–222.
104. Fishwick, C.; Higgins, J.; Percival-Alwyn, L.; Hustler, A.; Pearson, J.; Bastkowski, S.; Moxon, S.; Swarbreck, D.; Greenman, C.D.; Southgate, J. Heterarchy of transcription factors driving basal and luminal cell phenotypes in human urothelium. *Cell Death Differ.* **2017**, *24*, 809–818.
105. Bray, N.L.; Pimentel, H.; Melsted, P.; Pachter, L. Near-optimal probabilistic RNA-seq quantification. *Nature Biotechnology* **2016**, *34*, 525–527.
106. Soneson, C.; Love, M.I.; Robinson, M.D. Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. *F1000Research* **2015**, *4*, 1521.
107. Pimentel, H.; Bray, N.L.; Puente, S.; Melsted, P.; Pachter, L. Differential analysis of RNA-seq incorporating quantification uncertainty. *Nature Methods* **2017**, *14*, 687–690.
108. Lobban, E.D.; Smith, B.A.; Hall, G.D.; Harnden, P.; Roberts, P.; Selby, P.J.; Trejdosiewicz, L.K.; Southgate, J. Uroplakin gene expression by normal and neoplastic human urothelium. *Am. J. Pathol.* **1998**, *153*, 1957–1967.

